392 results about "Glycolysis" patented technology

The invention belongs to the technical field of biology, and relates to an escherichia coli engineering strain for producing L-isoleucine through a methyl malic acid way as well as a construction method and application of the escherichia coli engineering strain. According to the invention, Escherichia coli BW25113 is used as a chassis strain, and a methyl malic acid synthase high-activity mutant gene cimA3.7, an isopropyl malic acid isomerase gene GsleuCD, a 3-isopropyl malic acid dehydrogenase gene AfleuB and a leucine dehydrogenase gene Lsleudh are over-expressed; a methyl malic acid absorption protein gene is over-expressed, and a branched chain amino acid transport system is modified to improve the exosome of the L-isoleucine; all methyl malic acid pathway related genes are integrated to a genome of a chassis strain, and a plasmid-free L-isoleucine production strain is constructed; the copy number of a key gene on a genome is optimized, and the yield of the engineering strain L-isoleucine is increased by introducing a non-oxidative glycolysis approach. The yield of the L-isoleucine after the engineering strain is fermented for 34 hours in a fermentation tank is 56.6 g / L.

The invention discloses a personalized in-vitro total digestion glycolysis simulation system, and belongs to the technical field of in-vitro digestion simulation. According to the invention, by dynamically regulating and controlling the emptying amount and the flow velocity of digestive juice, the process of'digesting and absorbing at the same time 'in the small intestine is simulated, and the interaction of colon flora and colon organs is enhanced in combination with a micro-fluidic chip technology, so that the accurate detection of the digestion process and digestion products is realized. The digestion product simulated by the method disclosed by the invention and the flora structure are very close to the real in-vivo structure, so that the method has relatively high authenticity and credibility.

The invention discloses a method for simulating small intestine-colon dynamic digestion and glycolysis of polysaccharide-based food, and belongs to the technical field of food detection. The small intestine-colon simulated digestion and absorption system special for the polysaccharide-based food comprises a small intestine digestion simulation system, a sampling and emptying system, a large intestine glycolysis simulation system and a central intelligent control and display system (a pH control system, a temperature control system, a stirring rate control system, a gas path system and a flow rate control system). Aiming at the limitations that an existing human gastrointestinal tract digestion in-vitro simulation system cannot be continuous, is short in period and the like, the in-vivo real digestion and glycolysis physiological environment and process are simulated, intestinal peristalsis waves and digestion and glycolysis of polysaccharide-based food are simulated, automatic sampling can be achieved, generation of glucose in small intestines can be detected on line, and the in-vitro simulation system fits the real human physiological environment.

The invention discloses an anti-digestion polysaccharide-based food colon simulated glycolysis and multi-dimensional online analysis system, and belongs to the technical field of food. According to the method, glycolysis simulation of each colon part is completely carried out according to a human body digestion and glycolysis process and a physiological environment, and intestinal mucosa pellets are added to simulate a human body intestinal mucosa environment, so that the degradation process of partial microorganisms of the human body colon for resisting digestion of polysaccharide-based food is simulated under an in-vitro condition; and the glycolysis condition of the digested polysaccharide-based food entering the colon can be observed on line, and the device fits the real physiological environment of people.

The present invention addresses the problem of providing an improving agent for improving a stratum corneum barrier function without external replenishment with any moisturizing substance and a pharmaceutical composition containing said improving agent. The present invention provides: a stratum corneum barrier function improving agent which contains a glycolytic inhibitor as an active ingredient; the stratum corneum barrier function improving agent in which the glycolytic inhibitor is at least one selected from the group consisting of a glucose transporter inhibitor and a glucose competitive inhibitor; either of said stratum corneum barrier function improving agents having at least one selected from the group consisting of an inhibitory effect on the loss of skin moisture retention capacity and an inhibitory effect on skin permeability enhancement; and a pharmaceutical composition which contains any of said stratum corneum barrier function improving agents.

The invention belongs to the technical field of grease preparation, and particularly relates to a preparation method and application of diglyceride oil with a weight reducing effect. Comprising the following steps: firstly, adding grease into a basic nutrient solution, adding strains for fermentation, and filtering to obtain a glycolysis product; adding glycerol into the glycolysis product, carrying out lipase esterification reaction, and carrying out centrifugal separation to obtain an oil phase; the method comprises the following steps: degrading triglyceride by adopting dominant strain fermentation, then adding glycerol, and carrying out esterification reaction under the action of dominant compound lipase to obtain the diglyceride oil. According to the method, the 1, 3-diglyceride can be selectively generated, the proportion of dominant grease of the 1, 3-diglyceride can be increased, and research shows that the prepared diglyceride oil has good weight reduction and fat reduction effects and has a good application prospect.

Process for purifying bis (2-hydroxyethyl) terephthalate (BHET) from a crude solution obtained by glycolysis of ethylene glycol (EG) from polyethylene terephthalate (PET) waste containing at least one dissolved barrier polymer, water being added to the crude solution in a predetermined amount as an anti-solvent for the barrier polymer, and controlling the temperature to ensure that the solubility of the barrier polymer is significantly reduced without causing precipitation of BHET and its oligomer. Specifically, water is added to the crude BHET solution in at least two different stages, the weight ratio between EG and H2O is reduced, and the temperature is also reduced. In this way, the barrier polymer can be more effectively removed, and precipitation of BHET and its oligomer is not caused. Furthermore, in this manner, the volume of the liquid to be treated can be maintained within a relatively small value, thereby avoiding equipment defects associated with the treatment of large quantities of liquid by decantation and / or filtration, which may cause the process to be inconvenient from the industrial perspective.

The invention discloses a traditional Chinese medicine composition for treating aplastic anemia and application thereof, and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition comprises active substances, and the active substances are prepared from, by weight, 6-12 parts of semen cuscutae, 6-12 parts of fructus psoraleae, 6-12 parts of fructus ligustri lucidi, 10-14 parts of radix rehmanniae recen, 4-12 parts of radix scutellariae, 4-12 parts of cortex phellodendri, 10-20 parts of poria cocos, 10-30 parts of radix codonopsis, 6-12 parts of rhizoma atractylodis macrocephalae stir-fried with bran and 2-10 parts of radix glycyrrhizae preparata. The traditional Chinese medicine composition is low in cost, high in AA treatment effect and free of toxic and side effects, and has the effects of tonifying kidney, replenishing essence, detoxifying, descending turbidity and the like; the therapeutic effect on AA can be achieved by adjusting glycolysis of macrophages.

The invention discloses a yarrowia lipolytica engineering strain with high yield of resveratrol as well as construction and application of the yarrowia lipolytica engineering strain, and belongs to the technical field of synthetic biology and metabolic engineering. The invention provides a yarrowia lipolytica engineering strain. A 4-coumaric acid-CoA ligase gene, a multi-copy resveratrol synthase gene, a transketolase 1 gene, a fusion gene of a histidine phosphate aminotransferase gene and a tyrosine ammonia lyase gene, a glycolytic pathway hexokinase gene, a 6-phosphofructokinase-1 gene and a phosphoglycerate kinase gene are integrated, so that the recombinant protein is obtained. According to the present invention, by using glucose as the substrate, the high yield of resveratrol can be achieved by using glucose as the substrate, the resveratrol yield during shake-flask culture fermentation can achieve 3.157 g / L, the resveratrol yield can be increased to 30.7 g / L during 5L-scale fed-batch fermentation, and the resveratrol yield can be increased to 30.7 g / L when the resveratrol yield is increased to 30.7 g / L when the resveratrol yield is increased to 30.7 g / L when the resveratrol yield is increased to 30.7 g / L; the maximum value is reported by the yarrowia lipolytica system at present.

An ultrasound-metabolic synergistic system for diagnosing SLN metastasis of breast cancer. A deep learning model based on grayscale ultrasound is constructed to predict SLN metastasis of breast cancer, and 9 grayscale deep features and 15 grayscale manual features associated with SLN metastasis are obtained. A matrix material based on two-dimensional material MXene / multi-walled carbon nanotubes improves the detection of small metabolic molecules in blood, and metabolomics analysis results show that this has certain potential in detecting SLN metastasis of breast cancer, while revealing metabolic pathways closely associated with metastasis, such as the glucose-alanine cycle and glycolysis, suggesting that alterations in relevant molecular pathways may underlie heterogeneous features in ultrasound radiomics. The combination of ultrasound omics and metabolomics further improves the diagnostic performance for SLN metastasis of breast cancer. Therefore, organic integration of the two serves the diagnosis of SLN metastasis of breast cancer, providing a new strategy and theoretical basis for the accurate diagnosis of SLN metastasis of breast cancer, and possesses practical clinical application values.

The invention discloses a rice large-scale metabolism regulator DGP1 and crop metabolism quality design. The invention finds that the structural domain of the rice DGP1 family protein TIGR01589 targets a plurality of metabolic enzymes and promotes the metabolic enzymes to be transferred to a cell nucleus; the structural domain also has an intervention effect on a light breathing pathway by changing the composition of a glycine decarboxylase compound in mitochondria. Based on a molecular mechanism of DGP1, a chimeric protein ST containing a conservative structural domain and coupled with a chloroplast positioning signal is designed, and genetic engineering modification of pakchoi is realized. The modification strategy not only can guide substrate flow of a central glycolysis pathway to flavonoid biosynthesis, but also can promote accumulation of saccharides derived from photosynthetic products in leaves.

This disclosure describes the use of azithromycin, roxithromycin, and telithromycin, including derivatives thereof, as senolytic drugs. BrdU was used to induce senescence in model human fibroblast cell lines. Also disclosed are methods for screening compounds for senolytic activity. The SRB assay was used to measure cell viability through protein content. Azithromycin roxithromycin, and telithromycin, clinically-approved pharmaceuticals, were found to be senolytic drugs. However, the closely-related parent compound, erythromycin, showed no senolytic activity. Azithromycin strongly induced both aerobic glycolysis and autophagy in human fibroblasts, but showed bi-phasic effects including on mitochondrial oxygen consumption rates with inhibitory activity at 50 μM and stimulatory activity at 100 μM. The xCELLigence real-time assay system showed that azithromycin preferentially targets senescent cells, removing approximately 97% (nearly a 25-fold reduction in senescent cells).

The invention relates to the technical field of refined cotton processing, in particular to an efficient and optimized refined cotton processing production method which comprises the following production steps: S1, preparing materials: selecting cotton linters as raw materials; s2, cotton opening is conducted, cotton linters are placed on a feeding port of a cotton opener, and equipment is started for cotton opening treatment; s3, preparation of a cooking agent: taking quinone and 2-methylquinone as assistants, putting the assistants into sodium hydroxide, sodium carbonate and amino acid salt, and mixing and stirring to prepare the cooking agent; and S4, cooking treatment: putting the cotton linters into the prepared cooking agent, cooking, and reacting sodium hydroxide with cellulose. By regulating and controlling the biological thallus glycolysis process, directional control over the polymerization degree of the product is achieved, the range of the polymerization degree is narrowed, the fiber reaction uniformity is improved, the fluctuation range of the polymerization degree of products of the same specification is smaller than 80, the impurity removal efficiency is improved, the content of impurities, ash and metal ions is reduced, efficient impurity removal and refining are achieved, and the quality of processed refined cotton is improved.

The invention relates to a novel hexahydropyrroloindole alkaloid extracted from fructus lycii, which can effectively solve the problems of extracting and preparing the novel hexahydropyrroloindole alkaloid A from the fructus lycii and realizing the application of the novel hexahydropyrroloindole alkaloid A in preparation of medicines for preventing and treating type 2 diabetes mellitus. The novel hexahydropyrroloindole alkaloid A is prepared by the following steps: sequentially eluting with water, ethanol and acetone, carrying out reduced pressure concentration on an ethanol part, extracting, stirring a sample with silica gel, carrying out gradient elution, merging the same fractions, eluting a target component, stirring the sample with silica gel, carrying out gradient elution, collecting fractions within retention time, concentrating and drying, thereby obtaining the novel hexahydropyrroloindole alkaloid A in the preparation of the medicine for preventing and treating the type 2 diabetes mellitus and the application of the novel hexahydropyrroloindole alkaloid A in the preparation of the medicine for preventing and treating the type 2 diabetes mellitus. Glucose consumption in insulin-resistant HepG2 cells can be remarkably promoted, glucose uptake capacity is improved, glycogen synthesis is promoted, activity of glycolysis key enzymes hexokinase and pyruvate kinase is enhanced, development and application prospects are wide, and economic and social benefits are remarkable.

The present invention relates to a process for depolymerizing a polyester feedstock comprising opaque PET, which comprises: a) a conditioning step; b) a step of glycolysis, operated at between 180 and 400° C., a residence time of from 0.1 to 10 h in the presence of diol; c) a diol separation step, at a temperature of between 100 and 250° C., a pressure lower than that of step b) and producing a diol effluent and an effluent rich in monomers; d) a step of separating into a heavy impurities effluent and a prepurified monomers effluent, at a temperature of less than 250° C. and a pressure of less than 0.001 MPa and a residence time of less than 10 min; e) a step of decolourizing the prepurified monomers effluent, by adsorption of a mixture comprising between 20% and 90% by weight of the prepurified monomers effluent and a solvent, at a temperature of between 100 and 200° C., a pressure of between 0.1 and 1.0 MPa and in the presence of at least one adsorbent.

The invention relates to the technical field of microbiology and food processing, in particular to pediococcus acidilactici and application of the pediococcus acidilactici in preparation of a brain-intestinal axis regulating efficacy metagen product.The high-activity pediococcus acidilactici DY-1 is separated out from natural fermentation pickles of super-polyselenium plant cardamine violifolia for the first time; the strain can be widely applied to fermentation of high-selenium plant-based food, can significantly promote glycolysis release of selenium-containing active substances, has good acid resistance, high protease activity and high lipase activity, can fully ferment plant-based fermentation raw materials, and has high yield. Glycolysis of macromolecular substances such as protein, saccharides and fat is facilitated, accumulation of active ingredients such as essential amino acid, unsaturated fatty acid, alkaloid and phenolic substances is promoted, and the edibility and functionality of the product are improved; and the organic selenium-rich metagen product prepared by sterilizing the fermentation mixture can synergistically improve human body cognition and emotion regulation regulated by microorganism-intestinal-brain axis.

The invention discloses a hybrid central metabolic network chassis cell with both carbon atom economy and energy generation pathway as well as a construction method and application of the hybrid central metabolic network chassis cell, and belongs to the technical field of genetic engineering and microorganisms. The Escherichia coli central metabolic network is reconstructed, so that the Escherichia coli central metabolic network has a carbon sequestration module and an energy generation module at the same time. The carbon sequestration module continues to fix CO2 while avoiding CO2 release caused by pyruvic acid decarboxylation, the highest carbon yield can reach 133%, the carbon yield exceeds that of an NOG pathway reported only from the perspective of no CO2 release, and the carbon yield is two times that of a natural glycolysis pathway. And the direct product of the constructed mixed type central metabolic network is acetyl coenzyme A, and the acetyl coenzyme A contains an energy generation module, so that the chassis cell provided by the invention can meet the synthesis requirements of acetyl coenzyme A derivatives with high or low required reducing power, and has universality.

A genetically engineered bacterium that produces D-pantothenic acid and a construction method therefor, and the use of the engineered bacterium in the preparation of D-pantothenic acid by means of microbial fermentation. In the present invention, mainly by means of: (1) increasing the copy number of key genes in the pantoic acid synthesis pathway in Escherichia coli organisms to further make carbon flux flow to the synthesis of D-pantothenic acid, and (2) in order to keep enhancing the flow of carbon flux to the synthesis of D-pantothenic acid, negatively regulating a transcription factor by means of weakening the nitrogen limitation and activating glycolytic front-end genes to pull the carbon flow so as to save phosphoenolpyruvic acid and reduce the central carbon flow that enters TCA, an engineered strain for producing D-pantothenic acid with no plasmid or antibiotic addition is obtained. Finally, the titer of D-pantothenic acid in the shake flask is increased by 87.2% compared to that of the starting strain, and reaches 5.43 g / L. After fermentation in a 5-L fermentation tank for 84 hours, the yield of D-pantothenic acid can reach 94.2 g / L.

The invention belongs to the field of biological medicine, and particularly relates to PGK1 K17 site succinylation modification and application. Experiments show that the 17-site lysine of the PGK1 protein has succinylation modification (PGK1 K17su), and the existence of the modification is confirmed through a specific succinylation modified antibody for the first time. Further, it is found that PGK1 K17su can weaken lung cancer cell oxidative phosphorylation and promote glycolysis metabolism by inhibiting lung cancer cell mitochondrial generation, and functional experiments prove that PGK1 K17 succinylation modification promotes proliferation and migration of lung cancer cells.

The present invention relates to a process for preparing bis-(2-hydroxyethyl) terephthalate by depolymerization of a plastic filler comprising PET, comprising: a) a step of depolymerization of the PET in the presence of a diol, so as to have a weight ratio between the diol and the PET of the plastic filler of between 0.3 and 8.0, said step a) comprising a reaction phase operated between 150 and 300°C, b) a step of evaporation of the BHET to produce a BHET-rich stream and a heavy impurity stream, step b) using an evaporator comprising an evaporation zone and a zone for withdrawing the heavy impurity stream, and a section for discharging the heavy impurity stream located downstream of the evaporator, the evaporator being operated at a pressure less than or equal to 0.0010 MPa,and in which the evaporation zone is operated between 120 and 300°C and the heavy impurity stream withdrawal zone and the heavy impurity stream discharge section at a temperature greater than 250°C and less than or equal to 300°C.,

The present invention discloses a method for preparing a recycled copolyester and a heat-shrinkable film thereof, belonging to the field of waste polyester recycling. The method utilizes technologies such as glycolysis and methanol transesterification of waste polyester to produce recycled dimethyl terephthalate, which is then transesterified with other modifying monomers and ethylene glycol, followed by polycondensation, to produce the recycled copolyester. Finally, the recycled copolyester is directly delivered to the extrusion dies via a melt delivery pipeline and a metering pump to produce the recycled polyester heat-shrinkable film. The recycled polyester heat-shrinkable film exhibits high shrinkage, excellent toughness, and transparency, while also achieving high-value recycling of waste polyester.

The invention belongs to the technical field of pseudorabies virus prevention and control, and discloses application of BAY87-2243 in preparation of a drug for inhibiting pseudorabies virus proliferation, and the application is as follows: firstly, PK-15 is infected with a PRV-GD-WH strain, total RNA of cells is taken, and cDNA is obtained through reverse transcription; the change of the transcriptional level of a glycolysis key gene in a cell is detected through fluorescent quantitative PCR (Polymerase Chain Reaction) of an SYBR Green method. BAY87 is further used for acting on the HIF-1alpha, the regulation and control effect of the HIF-1alpha on glycolysis is verified, and finally, the virus load in cells is detected through SYBR Green fluorescent quantitative PCR (Polymerase Chain Reaction) and the inhibition effect of BAY87-2243 on PRV proliferation is determined through TCID50. Meanwhile, the invention also provides a pseudorabies virus inhibition drug.

The invention discloses a lactococcus lactis recombinant bacterium for expressing cyclic diadenylate and application of the lactococcus lactis recombinant bacterium. Homologous DAC is introduced into lactococcus lactis NZ9000, PDE is knocked out to improve expression of cyclic diadenylate in lactic acid bacteria, and meanwhile, the yield of a cyclic diadenylate precursor ATP is increased by increasing the expression quantity of glycolysis key enzyme PFK; and the ldh gene is knocked out to reduce the accumulation of byproducts, so that the yield of the inner ring diadenylate of the lactic acid bacteria is further improved.

The invention provides application of an ENO1K71R mutant as a target spot in screening preparations for regulating and controlling glycolysis of colon cancer cells and improving tumor microenvironment, and belongs to the technical field of biological medicine and molecular biology. The research on the colon cancer cells which stably knock down PCSK9 finds that PCSK9 achieves the regulation effect on lactic acid metabolism in the colon cancer cells by regulating ENO1 lactic acid modification, the blank of ENO1 protein lactic acid modification and the regulation effect of the ENO1 protein lactic acid modification in tumor progression is filled, a lactic acid modification site is verified by constructing an ENO1K71R mutation experience, and the result shows that the PCSK9 can be used for regulating the lactic acid metabolism in the colon cancer cells. After ENO1 (K71) point mutation, ENO1 lactic acid can be inhibited, a new site is provided for ENO1 lactic acid modification, and a theoretical basis is also provided for developing novel tumor targeted drugs.

The invention discloses a self-assembled PROTAC nano material based on natural product mitochondria targeting, which is a nano particle prepared from mitochondria targeting molecules, a photosensitizer and PROTAC as raw materials through a nano precipitation method. The mitochondrial targeting molecule is berberine, the photosensitizer is hypericin, and the PROTAC is dBET57; the ratio of the amount of substance of the dBET57 to the amount of substance of the berberine is (1-10): (1-10), and the ratio of the amount of substance of the dBET57 to the amount of substance of the hypericin is (1-10): (1-10). The nano material can be used for blocking multiple energy metabolism pathways of tumor cells, including glycolysis and oxidative phosphorylation, meanwhile, mitochondria is damaged, ferroptosis is induced, and the anti-tumor capacity of pharmacodynamic molecules is improved; bRD4 in tumor cells and downstream carcinogenic protein c-Myc of the BRD4 can be efficiently degraded. The invention also discloses an application of the nano material in preparation of antitumor drugs.

The invention discloses application of a JMJD6-targeted reagent in preparation of a medicine for promoting myocardial cell proliferation. The medicine can promote myocardial cell proliferation after myocardial infarction and reduce the myocardial fibrosis scar area caused by myocardial infarction. AAV9 myocardial specific overexpression virus and JMJD6 myocardial specific knockout mice are utilized, and the positive effect of JMJD6 in promotion of P1 cardiac apex resection of newborn mice and regeneration and repair of injured hearts after myocardial infarction of adult mice is disclosed for the first time; the specific mechanism is that JMJD6 depends on the activity of histone demethylase, enrichment of active modification H4R3me2a and H3R2me2s in a PDK4 promoter region is removed, transcriptional expression of the H4R3me2a and the H3R2me2s is inhibited, an impaired heart energy substrate utilization mode is stimulated to be increased and converted from fatty acid oxidation energy supply to glycolysis oxidation energy supply, and then adult myocardial cell proliferation is effectively promoted. The regeneration and repair capability of the heart after myocardial infarction is greatly improved, and a new effective target spot is provided for clinical treatment of myocardial injury.

The invention relates to application of thyroid hormone T3 in preparation of a medicine for delaying or treating intervertebral disc degeneration, and the thyroid hormone T3 can inhibit glycolysis capability of degeneration nucleus pulposus cells and reduce intervertebral disc lactic acid accumulation, so that nucleus pulposus cell senescence and apoptosis are relieved, and intervertebral disc degeneration is delayed or treated. Compared with the prior art, the technology for delaying or treating intervertebral disc degeneration by applying the thyroid hormone T3 provides new application of the thyroid hormone T3, the application value of the thyroid hormone T3 is greatly improved, the application range of the thyroid hormone T3 is expanded, the new field of application of the thyroid hormone T3 is expanded, and the thyroid hormone T3 has wide application prospects and commercial value.

The invention discloses an application of nicotinamide adenine dinucleotide in preparation of a medicine for treating keloid, and by researching the pathophysiological mechanism of keloid, it is found that mechanical related fibroblasts of keloid patients have metabolic reprogramming changes. Fibroblast populations which are mainly pathogenic to keloid have metabolic reprogramming caused by mitochondrial dysfunction, especially glycolysis level enhancement in cells and lactic acid accumulation. The medicine, namely NAD +, capable of regulating and controlling keloid fibroblast glycolysis and mitochondrial metabolism is found and verified through cell and animal experiments, and NAD + inhibits development of keloid by improving mitochondrial dysfunction, reducing lactic acid accumulation and inhibiting fibroblast migration and collagen synthesis. According to the invention, NAD +, which is a common medicine with good safety, is applied to keloid for the first time, and the scheme has small toxic and side effects and also has positive effects on oxidation resistance, aging resistance and cancer resistance, so that a new scheme is provided for treating keloid by medicines.

This disclosure describes the use of azithromycin, roxithromycin, and telithromycin, including derivatives thereof, as senolytic drugs. BrdU was used to induce senescence in model human fibroblast cell lines. Also disclosed are methods for screening compounds for senolytic activity. The SRB assay was used to measure cell viability through protein content. Azithromycin roxithromycin, and telithromycin, clinically-approved pharmaceuticals, were found to be senolytic drugs. However, the closely-related parent compound, erythromycin, showed no senolytic activity. Azithromycin strongly induced both aerobic glycolysis and autophagy in human fibroblasts, but showed bi-phasic effects including on mitochondrial oxygen consumption rates with inhibitory activity at 50 μM and stimulatory activity at 100 μM. The xCELLigence real-time assay system showed that azithromycin preferentially targets senescent cells, removing approximately 97% (nearly a 25-fold reduction in senescent cells).

A method of generating a hematopoietic cell, including providing a source cell and treating the source cell with a metabolic regulator that directs the source cell to preferentially use glycolysis or oxidative phosphorylation and / or cholesterol biosynthesis, wherein the source cell is differentiated into a GPA+ erythroid cell or a CD45+ non-erythroid cell. In some examples, the source cell is selected from the group consisting of a hemogenic endothelial (HE) cell, a iPS cell such as a differentiating iPS cell, a cell directly reprogrammed to a known pre-cursor of a hematopoietic cell, a cell directly reprogrammed to a hematopoietic cell or precursor of a hematopoietic cell, a reprogrammed cell that is subsequently further reprogrammed to a hematopoietic cell or precursor of a hematopoietic cell, an adult hematopoietic cell derived from bone marrow or mobilized peripheral blood and a neonatal hematopoietic cell derived from cord blood or prenatal tissue (e.g. placenta). Some examples involve metabolically regulating a lipid biosynthesis pathway with an inhibitor of the lipid biosynthesis pathway or metabolically regulating a histone acetylation pathway with an inhibitor of the histone acetylation pathway.